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Introduction
In the present issue of Breast Cancer Research, Kim and
colleagues [1] demand the development of ‘an authentic
breast cancer model’. Based on suggested shortcomings
of genetically engineered mice (GEM), the authors con-
clude that this goal can merely be achieved by improving
xenograft models. In this commentary, I will briefly highlight
the latest technological advances in the generation of
mouse models for breast cancer and will dispute some of
the suggested limitations of GEM. Based on recently pub-
lished findings, I will also critically review the proposed
species-specific function of genes (in particular, the role of
telomerase) during carcinogenesis in humans and rodents.
Furthermore, I will discuss technical improvements of
xenografting human epithelia along with appropriate
stromal components into immunocompromised rodents. In
this context, I will also list five arguments to caution unreal-
istic expectations on the authenticity of these newly devel-
oped xenograft models to faithfully mimic the human
disease.
For a basic understanding of the concepts and terminol-
ogy of xenograft models please refer to the article by Kim
and colleagues [1] in the present issue. I would also like to
draw the reader’s attention to a more comprehensive
review by Van Dyke and Jacks [2] that discusses in
greater detail the technical advances in manipulating the
murine genome.
Models and reality: a dialectic liaison
When can we expect to have an authentic mouse model
for breast cancer? This frequently asked question clearly
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Abstract
Rodent models for breast cancer have for many decades provided unparalleled insights into cellular
and molecular aspects of neoplastic transformation and tumorigenesis. Despite recent improvements
in the fidelity of genetically engineered mice, rodent models are still being criticized by many
colleagues for not being ‘authentic’ enough to the human disease. Motives for this criticism are
manifold and range from a very general antipathy against the rodent model system to well-founded
arguments that highlight physiological variations between species. Newly proposed differences in
genetic pathways that cause cancer in humans and mice invigorated the ongoing discussion about the
legitimacy of the murine system to model the human disease. The present commentary intends to
stimulate a debate on this subject by providing the background about new developments in animal
modeling, by disputing suggested limitations of genetically engineered mice, and by discussing
improvements but also ambiguous expectations on the authenticity of xenograft models to faithfully
mimic the human disease.
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illustrates that breast cancer is still considered one spe-
cific disease. However, various types of human breast
cancer differ significantly in their morphology, their
histopathology, their dependence on endogenous growth
factors, their activation/inactivation of specific genes, and,
most of all, their clinical outcome. For example, the latest
studies distinguish at least four or five breast cancer types
based solely on hierarchical clustering of gene expression
profiles [3,4]. The term ‘breast cancer’ thus does not
stand for a specific disease, which is genetically and phe-
notypically uniform. It is, therefore, a misapprehension to
envision a single model system that could mimic all fea-
tures of breast cancer. Based on this fact alone, it is likely
there will be more than just one ‘authentic model’ to reca-
pitulate human breast cancer(s).
The general definition of a model (Latin modulus, small
measure) is that it reflects only certain aspects of the origi-
nal. It might be just a philosophical exercise to argue
whether a model as such can ever be ‘authentic’ or identi-
cal to the original. From an ideal animal model for human
breast cancer we expect that it faithfully reflects the
human disease on various levels such as etiology, pathol-
ogy, and genetics, that cancer originates only in the
mammary gland, that neoplasia occur with a 100% inci-
dence in treated or modified animals, whereas control
animals do not develop tumors, and that tumorigenesis
should have a relatively short latency.
After careful consideration of all these expectations, one
might ask whether it will ever be possible to establish
ideal animal models. For instance, to model tumorigene-
sis in a relatively short period in the mouse we need to
introduce shortcuts (i.e. precise mutations in the exact
sequential order in which they might occur over several
years or decades in the human). In the end we might
obtain models that carry almost identical genetic alter-
ations of oncogenic pathways as we can distinguish
them today. But does each step toward neoplastic
transformation recapitulate the morphology, pathology,
and etiology of the progressing disease? For now, we
do not even have a complete map of all genetic alter-
ations that occur in specific forms of breast cancer, nor
do we have a genuine concept about the precise
sequence of events that take place during cancer pro-
gression. The generation of models for breast cancer
that accurately reflect all the characteristics mentioned
is therefore a distant goal that does not even seem to
emerge on the horizon. Nevertheless, one should be
aware of the fact that we will always read about models
that are highlighted as being ‘authentic’. Whether such
claims are reasonable, however, depends largely on
how we interpret a model in its capability to reflect
certain features of breast cancer, and whether we
accept imperfections when we have a closer look at all
other characteristics.
Main categories of mouse models for human
breast cancer
Mouse models for human breast cancer can be catego-
rized into three main groups: xenograft models; chemically
induced, virally induced, or ionizing radiation-induced
models; and GEM such as transgenics and knockouts.
Certain models rely on a combination of techniques used
to generate these three main types of cancer models. One
example is a knockout mouse that was treated with a car-
cinogen or with ionizing radiation. To date, genetically
engineered mouse strains are used primarily as tools to
study the biological function of genes during neoplastic
transformation and tumorigenesis. The US Food and Drug
Administration is, however, considering altering the guide-
lines on preclinical testing for the carcinogenicity of phar-
maceuticals (see the earlier article by Durso [5]), and
specific strains are now being used in selective chemo-
prevention and chemotherapy trials (for examples, refer to
Van Dyke and Jacks [2]).
Among the mouse models for breast cancer, xenografts
still play the dominant role in preclinical trials. The reasons
for this are manifold. First, xenograft models are relatively
inexpensive and easy to generate. Also, the subcutaneous
or orthotopic injection of tumorigenic human breast
cancer cells such as the metastatic human breast adeno-
carcinoma cells (MCF-7) or the metastatic human breast
ductal carcinoma cells (T-47D) into immunocompromised
recipients results in the formation of solid tumors after a
relatively short latency. Third, xenograft models that utilize
estrogen receptor (ER)-positive cancer cell lines are cur-
rently indispensable for preclinical testing of inhibitors of
steroid receptor signaling and drug resistance studies.
Approximately 50% of all human breast cancers are
ER-positive, but the vast majority of mammary lesions in
GEM are ER-negative. Most GEM thus do not precisely
recapitulate steroid receptor signaling during neoplastic
transformation. Based on the studies by Medina and col-
leagues (for references, see [6]), however, it is established
that steroid and peptide hormones have a considerable
effect on the initiation of mammary tumorigenesis in mice.
As an alternative to human breast cancer cell lines and
xenograft models, studies on steroid signaling and
mammary cancer are being performed in rat models that,
unlike mice, exhibit a significantly higher frequency of
ER-positive lesions. The latest developments in the tar-
geted manipulation of the rat genome [7] hold great
promise for the improvement of rat models to study estro-
gen signaling and tumorigenesis in vivo.
Of mice and men
Xenograft models seem to gain importance for mechanis-
tic studies since it has been proposed that, compared
with murine cells, human mammary epithelial cells have to
alter additional molecular pathways to achieve neoplastic33
transformation. This theory, recently advocated by Hahn
and Weinberg [8], was highlighted in the article by Kim
and colleagues [1] in the present issue. Based on the con-
clusions by Hahn and Weinberg it seems essential to
develop new xenograft models for breast cancer that
reflect the suggested differences to the rodent system.
The initial findings by Hahn and Weinberg were significant
but, based on newer findings, it is necessary to revisit the
proposed differences and to challenge overly simplistic
views on molecular events leading to tumorigenesis in
humans and mice.
The theory of a ‘one-hit kinetics of tumorigenesis’ attrib-
uted to GEM by Kim and colleagues [1] is in sharp con-
trast to current views about the hallmarks of cancer
initiation and progression [2,9]. Unlike in immortalized cell
lines that lack important tumor suppressor pathways, no
oncogene alone is able to instantaneously transform
normal mouse mammary epithelial cells in vivo. This is indi-
cated by two lines of evidence: tumors arise in GEM after
a certain latency period; and, despite a widespread
expression of the oncogene throughout the entire gland,
tumors arise as focal lesions, suggesting that multiple
genetic alterations have to occur to promote neoplastic
transformation in transgenic models. The latter argument
is also supported by the fact that transformation is
reversible at defined stages of tumorigenesis when the
oncogene is turned off [10–12]. Again, as in humans,
mammary epithelial cells in rodents need multiple genetic
defects before uncontrolled cell growth and tumorigenesis
can occur in vivo.
In their initial study, Hahn and colleagues [13] use defined
genetic elements to transform primary human fibroblasts.
The same strategy was used recently by Elenbaas and
colleagues [14] to generate human breast cancer cells in
vitro that form tumors in immunocompromised animals.
The necessary genetic elements to transform human cells
were defined as simian virus 40 (SV40) large T antigen, as
the Harvey rat sarcoma virus oncogene (H-ras), and as the
telomerase catalytic subunit (TERT). Large T antigen
inhibits a broad spectrum of oncogenic pathways, most of
all p53 and Rb, and it is known that this protein can inacti-
vate various members of the Rb gene family such as
retinoblastoma protein (pRb), p107, and p130. Despite
these refinements of transforming human cells in vitro, one
should recognize that the new xenograft model by Elen-
baas and coworkers cannot serve as a genuine model for
human mammary neoplasia. First, SV40 large T antigen
has not been linked to the etiology of human breast
cancer. Also, like any other conventional xenograft model,
the cancer cells are able to form tumors without the
appropriate microenvironment. Third, despite inclusion of
human fibroblasts that seem to support the multiplication
of the tumorigenic cells, the histopathological appearance
of this xenograft model does not resemble human breast
cancer (see later). In conclusion, it would be a necessity
for the development of new xenograft models to introduce
defined mutations into tumor susceptibility loci of immor-
talized human epithelial cells as they occur in vivo in
human carcinoma.
It is not absolutely clear to date what these defined muta-
tions and genetic elements are. One genetic pathway has
already been overlooked in the primary study by Hahn and
colleagues [13]. Other workers found that the defined
genetic elements mentioned earlier were not sufficient for
the transformation of primary human cells. For instance,
the inactivation of p53 and pRb using human papillo-
mavirus E6 and E7 oncoproteins instead of SV40, in com-
bination with H-ras and TERT, did not result in neoplastic
transformation [15]. Although Elenbaas and colleagues
predicted the presence of a small t protein in addition to
the large T antigen expressed by the SV40 early region, it
was a year later when Hahn and colleagues [16] recog-
nized the essential role of small t antigen as the transform-
ing agent by inhibiting isoforms of the protein
phosphatase 2A. There are now five suggested pathways
that are important for neoplastic transformation (p53, pRb
family, TERT, H-ras, and protein phosphatase 2A), and one
might ask whether there are more to be identified since the
‘defined’ elements used to transform cells are not directed
against one particular member of these pathways.
Another important question remains: how different are
these pathways in human versus murine cells? All the
pathways already listed have been linked both individually
and in combination to mammary tumorigenesis in the
mouse. Appropriate mouse models have been genetically
engineered and analyzed in great detail. For a narrative of
various models, see the February 2000 special issue of
Oncogene. The prime paradigm that is frequently used to
exemplify the ‘fundamental’ differences between these two
species is the function of telomeres and telomerase
(TERT) to limit the life span in human cells [17]. It is often
stated (see also the article by Kim and colleagues [1])
that, in contrast to the human cells, murine cells have very
long telomeres and a basal telomerase activity. As one
hallmark of neoplastic transformation, human cells have to
(re)activate TERT to achieve immortality. (Of note, one
should know that the generalized statement about the
telomere length in mice is incorrect. Unlike Mus musculus
that we currently use to generate GEM, Mus spretus has
telomeres of approximately the same length as humans
[18]. Species-specific variations in telomere length there-
fore cannot serve as an indicator for an expected lifespan.)
Several lines of evidence exist to suggest that telomeres
and TERT also play an important role in mammary tumori-
genesis in GEM. It has been reported that the activity of
telomerase was elevated in mouse mammary tumor virus-
neu-derived tumors compared with normal mammary
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epithelia [19]. Second, the overexpression of TERT in
transgenic mice resulted in the development of invasive
mammary carcinomas [20], suggesting that there are
cancer-promoting, telomere-independent functions of
TERT. This conclusion is supported by the fact that a
mutant of TERT lacking the capability of extending telom-
eres still retains its tumorigenic properties in cells that use
alternative mechanisms of telomere maintenance [21].
Third, the lack of telomerase function greatly inhibits
tumorigenesis in cancer-prone Cdkn2a knockout mice
[22]. Also, the targeted mutation of the Terc gene, which
encodes the RNA subunit of TERT, results in telomere
shortening that, in turn, leads to end-to-end fusions and
subsequent chromosome breaks and translocations. In
the absence of functional p53, these knockout mice have
a higher susceptibility to develop carcinomas. Like
human cancers, these lesions possess nonreciprocal
translocations [23]. In summary, telomere and telom-
erase function is critical for tumorigenesis in both human
and murine cells.
The final issue that I would like to discuss in this context is
whether the re-activation of TERT is really a prerequisite
for the multiplication of tumor-initiating cells (‘breast
cancer stem cells’) in the human breast. Hanahan and
Weinberg [9] did not completely reject the possibility that
growth arrest of human cells in culture might be a techni-
cal artifact. According to the study by Elenbaas and col-
leagues [14], it is obligatory to introduce TERT into
mammary epithelial cells in culture to bypass senescence.
This seems to be a logical approach since, with the excep-
tion of stem cells, most other somatic cells in humans do
not express telomerase. It is, however, interesting to note
that human mammary epithelial cells can apparently be
propagated for at least five passages without signs of
senescence and without exogenous TERT expression
under culture conditions that maintain cells in an undiffer-
entiated state [24]. According to the latter study, these
special culture conditions, in which epithelial cells are
grown in a nonadherent fashion as mammospheres, allow
the enrichment of early progenitor or stem cells. It would
be logical to assume that these mammary epithelial prog-
enitor cells have active telomerase and, therefore, an
extended replicative potential. However, a difference in
TERT expression between these progenitor cells and dif-
ferentiated cells was not reported.
An interesting subject of future studies is to examine
whether mammary stem cells in the human breast express
telomerase. Without TERT expression how do they other-
wise maintain their replicative potential? The idea that
undifferentiated progenitors are the cancer-initiating cells
in the human breast is currently a very popular theory that
is based on various findings in humans and mice [25–28].
If ‘breast cancer stem cells’ have residual expression of
telomerase, this might explain why these cells are prime
targets for transformation. In this case they would not
need an additional mutation to reactivate the TERT gene
during tumorigenesis. Since we already know that many
somatic cells in mice express TERT, the stem cell theory
of human breast cancer would logically imply that cancer-
initiating cells in both species have the same extended or
limitless replicative potential. A confirmation of this hypoth-
esis would probably be the end of the discussion about
fundamental differences of TERT function in mouse and
human cells.
Modeling molecular events for initiation of
mammary tumorigenesis
Kim and colleagues [1] state that tumors occurring in mice
must have an accelerated program of progression since
mice have a shorter lifespan than humans. This general
statement does not just apply for GEM, but it is also rele-
vant for xenografts. Xenograft models with rodents as
recipients could not be established if it would take many
years or decades for a human premalignant lesion to
progress into metastatic breast cancer. This issue needs
to be addressed when new objectives are articulated to
develop ‘authentic’ xenograft models on the basis of
immortalized or precancerous human epithelial cells. Most
human cells that are used for xenotransplantation today
are already fully neoplastic and form tumors in immuno-
compromised animals after a short latency without the
appropriate stromal environment.
Wild-type mice do not develop mammary tumors during
their lifetime unless they are inbred strains that carry
mouse mammary tumor virus or other selected mutations.
In all types of mouse models, we introduce mutations to
initiate and speed up neoplastic transformation. Trans-
genic strains that express oncogenes under mammary-
specific promoters were the first generation of GEM for
breast cancer [29,30]. In a subset of these strains, preg-
nancy hormones greatly induce the expression of a partic-
ular oncogene, leading to an increased tumor incidence in
parous animals. This is not necessarily a limitation of these
early mouse models since humans also show a transient
increase in breast cancer risk after a term pregnancy. The
protective effect of pregnancy on breast cancer that Kim
and colleagues [1] mention in their article is a long-term
effect, which becomes statistically significant several
years post partum. For more information on this subject
see the summary report of a recent workshop on preg-
nancy and breast cancer (http://www.cancer.gov/cancer-
info/ere). To avoid pregnancy-induced oncogene
expression, newly developed transgenic strains now use
the native promoter of an oncogene [31] or hormonally
nonresponsive promoters [32]. It is interesting to note that
some of these new strains seem to develop neoplastic
lesions that express ER [32], suggesting that it might be
technically possible to model ER-positive breast cancer in
GEM (see earlier discussion).
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The second generation of GEM comprises conventional
knockouts with targeted mutations of tumor susceptibility
genes.  p53, Rb, and Cdkn2a knockout mice are well-
known examples. However, these strains develop a dis-
tinct tumor spectrum that differs from humans with
inherited germline mutations in these tumor suppressors.
In particular, most p53-deficient mice succumb to lym-
phoid neoplasia before they develop carcinomas. Since
ductal elongation and branching morphogenesis occur pri-
marily in pubescent animals, we can perform a transplanta-
tion of mammary epithelia into wild-type recipients to
establish mice lacking p53 specifically in the mammary
ducts [33].
Early embryonic lethality of other important mouse models
for breast cancer, such as breast and ovarian cancer
gene 1 and gene 2 (Brca1 and Brca2) knockouts, led to
the development of the third and most current generation
of GEM: conditional knockout mice [34,35]. This major
refinement in manipulating the murine genome utilizes the
Cre recombinase from bacteriophage P1, which catalyzes
the excision of an essential element of a target gene (for
instance a coding exon) located between two loxP (locus
of X-ing) recognition sites. This technology enables us to
delete a tumor susceptibility gene from virtually any cell
type at any given time point during development. This also
includes the deletion of any given gene in cells that have
undergone neoplastic transformation to study tumor pro-
gression or to mimic a therapeutic approach with genetic
means. More importantly, this technology can also be
used to model hereditary breast cancers as well as spo-
radic mutations in a limited number of somatic cells. For
instance, the Cre-lox-mediated deletion of Brca1 from
developing mammary epithelial cells resulted in tumorigen-
esis. In addition, these conditional mutants allowed us to
examine important functions of p53 in preventing an early
onset of the disease [35].
In summary, many of the technical limitations that were
innate in earlier generations of GEM (see Kim and col-
leagues [1]) are already a relic of the past. Nevertheless,
it still needs to be established whether these newly devel-
oped GEM resemble important features of human breast
cancer such as histopathology, dependence on endoge-
nous growth factors, and formation of metastases. The
consensus report of the Annapolis Meeting on
histopathological features of mouse models for breast
cancer was primarily focused on transgenic mice along-
side chemically induced and virally induced mammary
tumor models [36]. It is therefore desirable to assemble a
panel of comparative pathologists to validate these newly
developed strains.
The importance of the stroma
There are obvious differences between rodents and
humans regarding mammary morphogenesis, and this dis-
tinction is not just noticeable on the anatomical level (e.g.
number and location of glands). One important distinction
between mice and humans is the composition of the
mammary stroma. Pathologists use this feature to distin-
guish human and murine mammary lesions. While the
mouse mammary stroma largely consists of adipose
tissue, the human stroma contains a relatively high
amount of fibrous cells surrounding the epithelial com-
partment. This may be one reason why particular lesions
in GEM do not closely resemble human breast cancers
on the histopathological level. The difference in the
stromal environment may also be considered a reason
why primary human breast cancers are difficult to grow in
immunocompromised mice. Normal and transformed cells
do not just need an adequate amount of the right hor-
mones, but also need an appropriate microenvironment,
which supports epithelial cells with local growth factors.
In turn, epithelial cells signal back to the stroma, which
then becomes competent to support epithelial prolifera-
tion and differentiation [37]. For a summary of the main
functions of the mammary stroma and the role of various
paracrine factors, refer to a recent review by Wiseman
and Werb [38].
Novel xenograft models that utilize fibroblasts derived
from the human mammary gland attempt to address the
issue of generating the correct microenvironment for
human epithelial cells [39]. These features will undoubt-
edly significantly improve existing xenograft models that
use untransformed epithelial cells. The co-transplantation
of the correct stroma is, however, only needed when
normal and preneoplastic cells still depend on local
growth factors. The vast majority of human breast cancer
cell lines that are used in xenograft models today lack that
requirement. The newly designed breast cancer model
described by Elenbaas and colleagues [14], which uti-
lizes in vitro transformed cells, shows some increase in
the efficiency of tumor formation when these cells were
co-implanted with normal human fibroblasts, suggesting
that local growth factors have an effect on the prolifera-
tion of these neoplastic cells. Tumorigenesis in this model
is, however, not completely dependent on the human
stroma. Nevertheless, one important requirement of newly
designed xenograft models is that they, unlike many
GEM, mimic human breast cancer on the histopathologi-
cal level (see Kim and colleagues [1]). This is clearly not
the case in the model of Elenbaas and colleagues. The
addition of fibroblasts resulted in tumors that were histo-
logically similar to those tumors arising when malignant
cells were injected alone.
In addition to these technical issues that obviously need to
be resolved, xenograft models have other, more important
limitations. The shortage of applicable techniques to intro-
duce precise mutations into endogenous genes of non-
immortalized and untransformed primary mammary
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epithelial cells as they might occur during human breast
carcinogenesis was discussed earlier.
Second, in order to generate a xenograft model, immortal-
ized human cells (stroma and epithelia) need to be trans-
planted into immunocompromised animals. The lack of a
normal immune response against tumor cells is a common
weakness for using xenograft models in preclinical trials
since a number of cancer therapies rely directly or indi-
rectly on an intact immune system. In particular,
immunotherapy uses strategies to suppress tumor growth
by attempting to promote rejection of the tumor through
cell-mediated immunity in the host. To generate such a
complex mouse model one would have to reconstitute the
matching human immune system in addition to the human
stroma–epithelia graft in the mammary gland.
Also, human precancerous cell lines are difficult to estab-
lish and maintain in a stable condition. Genetic drift will
affect precancerous human epithelial cells and immortal-
ized stroma cell lines in the same way as existing models
that utilize MCF-7 or T-47D cells.
A fourth limitation is that the tissue-recombination
approach might reconstitute a correct epithelial–stromal
interaction in the primary mammary cancer in the xenograft
model. Therapeutic regimens have been proposed to
target the cancer-associated stroma in addition to cancer
cells. The use of this strategy clearly becomes inappropri-
ate for the treatment of metastasizing breast cancer in this
xenograft model. Assuming that neoplastic epithelial cells,
but not normal fibroblasts, invade other organs, one should
expect that, unlike in the primary tumor, cancer cells inter-
act with the murine stroma in lung or bone metastases. In
this regard, improved xenograft systems might not be dif-
ferent from conventional models. The use of transformed
stromal cells that might metastasize along with malignant
epithelial cells as suggested by Kim and colleagues [1] has
not been proven to work and, more importantly, this strat-
egy does not mimic what happens in human breast cancer.
Finally, it is assumed that the tissue recombination
approach will model all necessary growth factors to
support normal proliferation and differentiation of epithelial
cells. This strategy focuses on local growth factors that
act mostly in a paracrine fashion, but it does not reflect
species-related incompatibilities of systemic factors pro-
duced by the host with the corresponding receptors of the
graft. The implementation of this condition in the model
design requires the expression of human hormones at
near-physiological levels in the immunocompromised host.
Before this long-term goal can be achieved it will be nec-
essary to examine what effects such a ‘hormone replace-
ment’ with ligand-receptor incompatibility will have on the
general physiology and reproductive capability of the
animal model.
Some current challenges
Several shortcomings of GEM and xenograft models have
been discussed. While most existing cancer models today
represent early stages of mammary tumorigenesis, many
of them do not recapitulate advanced human breast
cancers; in particular, the frequency and location of meta-
stases. The establishment of mouse models that show a
high frequency of metastasis to the bone is an important
aim that needs to be addressed in the future. To achieve
this goal it is necessary to re-examine existing animal
models, in particular, the newly developed GEM and
xenografts, for their ability to develop micrometastases in
the bone. In this context, new imaging technologies will
allow us to visualize tumors noninvasively, to quantify their
progression including neovascularization, to guide us pre-
cisely to locations of distant metastases for histopatholog-
ical examination, and to assess responses to therapeutic
regimens.
Another future goal is the targeted modification of the
murine stroma to achieve a more human-like appearance
without compromising the normal function of the gland.
The nature of pregnancy-related, permanent changes in
the gland is another important subject of current investiga-
tions. It has been shown that pregnancy results in a per-
sistent alteration of the expression profile of various genes
[40,41], and not all cells that express advanced differenti-
ation markers undergo apoptosis during involution at the
end of lactation [42]. Interestingly, these surviving cells are
unique for parous females and have certain properties of
multipotent stem cells. A closer examination of these cells
might explain the differences in gene expression men-
tioned earlier and the variations in tumor susceptibility
between mammary tissues of nulliparous and parous
females [43].
The identification and characterization of multipotent stem
cells in normal breast tissue and animal models for breast
cancer is another hot topic. While discussing the function
of telomerase in breast cancer, I mentioned several open
questions regarding the involvement of stem cells during
tumorigenesis. The identification of cancer-initiating
epithelial subtypes (i.e. ‘cancer stem cells’) is of utmost
importance to understand the process of tumorigenesis. In
turn, it is essential to target the correct epithelial subtype
to study the function of tumor susceptibility genes. Various
GEM use different regulatory elements to target a gene of
interest to diverse epithelial subtypes in different compart-
ments of the gland. In addition, it also needs to be consid-
ered that some oncogenes function as paracrine factors,
suggesting that the cells expressing the oncogene might
not necessarily be those that become malignant. Hence,
without knowing what are the cancer-initiating cells in par-
ticular models, it is difficult to directly compare one with
another and to draw conclusions about the relevance of
certain signaling pathways.
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The following is an example that might illustrate the impor-
tance of targeting the correct epithelial subtype. Based on
the expression of keratin 8, keratin 18, and keratin 19 in
breast cancers, it is generally accepted that luminal
epithelial cell types contribute mainly to neoplastic trans-
formation in the human breast [44–46]. Many observa-
tions in mouse models for breast cancer support this
paradigm [36]. Keratin 14 (K14) is predominantly
expressed in myoepithelial cells in the adult breast, and
these rarely contribute to malignant lesions [44]. The dele-
tion of Brca2 from luminal epithelial cells using whey-
acidic-protein-(WAP)-Cre mice is entirely sufficient to
render these cells susceptible to neoplastic transformation
[47]. The majority (16 out of 23) of Brca2-deficient tumors
were p53-positive and p21Cip1-positive. In contrast, the
excision of the Brca2 gene from the ‘mammary gland’
using K14-Cre mice did not cause mammary tumorigene-
sis [48]. Only in combination with a p53 null mutation did
K14-Cre Brca2 floxed mice develop tumors. Hence, the
phenotype of both Brca2-deficient models and the mecha-
nistic implications about p53 function are strikingly differ-
ent. Unfortunately, the latter report did not provide
adequate information about whether the tumors arose
solely from K14-positive myoepithelial cells to draw a final
conclusion about the cellular origin of these lesions.
In summary, the generation of animal models for breast
cancer is becoming increasingly complex. It is therefore
essential that one pays close attention to the details of the
experimental design, such as targeting the desired epithe-
lial subtype, when utilizing genetic tools to model
mammary carcinogenesis.
Conclusions
Mouse models for breast cancer are valuable to study mol-
ecular pathways of neoplastic transformation and tumori-
genesis  in vivo, and they serve as tools for selected
preclinical trials. Breast cancer is not genetically and phe-
notypically uniform, and therefore one model system will
never be enough to recapitulate various forms of the
disease. Whether a model system is ‘authentic’ to human
breast cancer is determined by its capability to reflect
certain features of the disease, but it is unrealistic to
expect that one model can mimic all aspects of human
breast cancers. The superiority of one model over another
largely depends on the scientific hypothesis, on experi-
mental design, and on the type of study that one wishes to
perform.
The majority of animal models are readily available for bio-
logical studies at academic institutions around the world.
The Mouse Model for Human Cancer Consortium even
distributes the newest cancer models free of charge (for
more information, see http://mouse.ncifcrf.gov). Scientists
are also encouraged to enter supplementary information
about their cancer models into a central database
(http://cancermodels.nci.nih.gov). This resource might be
a valuable tool to decide whether a certain model has the
desired features of breast cancer that one plans to
examine and whether a model is suitable for testing thera-
peutic strategies.
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